Bone and Body Comp: A Sub Study of the SECOND-LINE Study
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The use of anti HIV drugs (ART), and in particular a class of drugs known as nucleoside reverse transcriptase inhibitors (N(t)RTI), has been associated with changes in body fat and in particular loss of peripheral fat in the limbs. Low bone mineral density and osteoporosis are also common in HIV-infected patients. There appears to be some association between ART and bone loss, but this is poorly understood and requires further research. The SECOND-LINE study provides an opportunity to examine if a new anti-HIV drug (raltegravir) can result in greater increase in limb fat than a drug regimen containing N(t)RTI, which is currently standard of care. This study also provides an opportunity to examine if additional bone loss occurs with the second regimen of anti-HIV drugs and whether non-N(t)RTI regimens of ART used in second line therapy result in more or less bone loss than use of other classes of anti-HIV drugs such as protease inhibitors or N(t)RTI combinations.
It is hypothesized that subjects randomised into Raltegravir arm will demonstrate greater increases in limb fat and smaller reductions in bone density at the proximal femur over 48 weeks than those randomised into the control arm (LPV/r + 2-3N(t)RTIs).
| Condition | Intervention | Phase |
|---|---|---|
|
HIV |
Drug: Lopinavir / ritonavir + 2-3N(t)RTI Drug: Lopinavir /ritonavir + raltegravir |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
- Mean limb fat and bone mineral density changes as measured by DXA scan [ Time Frame: May 2013 ] [ Designated as safety issue: No ]
| Enrollment: | 211 |
| Study Start Date: | February 2010 |
| Estimated Study Completion Date: | August 2013 |
| Primary Completion Date: | September 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Active Comparator: Arm 1. Lopinavir / ritonavir + 2-3N(t)RTI |
Drug: Lopinavir / ritonavir + 2-3N(t)RTI
LPV/r 200mg/50mg 4 tabs once daily or 2 tabs twice daily + 2-3 N(t)RTI
|
| Active Comparator: Arm 2. Lopinavir /ritonavir + raltegravir |
Drug: Lopinavir /ritonavir + raltegravir
LPV/r 200mg/50mg 4 tabs once daily or 2 tabs twice daily + raltegravir 400mg 1 tablet twice daily.
|
Eligibility| Ages Eligible for Study: | 16 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- HIV-1 positive by licensed diagnostic test
- Aged 16 years or older (or minimum age as determined by local regulations or as legal requirements dictate)
- Have received first antiretroviral regimen consisting of an NNRTI plus 2N(t)RTIs for ≥ 24 weeks
- No change in antiretroviral therapy within 12 weeks prior to screening
- Failed first-line NNRTI + 2N(t)RTI combination therapy according to virological criteria defined by two consecutive (≥7 days apart) HIV RNA results of > 500 copies/mL
- No prior or current exposure to HIV protease inhibitors and/or HIV integrase inhibitors
- Able to provide written informed consent
Exclusion Criteria:
The following laboratory variables:
- absolute neutrophil count (ANC) < 500 cells/µL
- hemoglobin < 7.0 g/dL
- platelet count < 50,000 cells/µL
- ALT > 5 x ULN
- Pregnant or nursing mothers
- Participants with active viral hepatitis B infection defined by the presence in serum of hepatitis B surface antigen
- Use of immunomodulators within 30 days prior to screening
- Use of any prohibited medications (rifampicin, midazolam, triazolam, cisapride, pimozide, amiodarone, dihydroergotamine, ergotamine, ergonovine, methylergonovine, astemizole, terfenadine, vardenafil, and St. John's wort)
- Intercurrent illness requiring hospitalisation
- Active opportunistic disease not under adequate control in the opinion of the site Principal Investigator
- Participants with current alcohol or illicit substance abuse that in the opinion of the site Principal Investigator might adversely affect participation in the study
- Participants deemed by the site Principal Investigator unlikely to be able to remain in follow-up for the protocol-defined period
Contacts and Locations| Argentina | |
| CEADI | |
| Buenos Aires, Argentina | |
| India | |
| YRGCare Medical Centre | |
| Chennai, India, 600113 | |
| Malaysia | |
| University of Malaya Medical Centre | |
| Kuala Lumpur, Malaysia, 50603 | |
| South Africa | |
| JOSHA Research | |
| Bloemfontain, South Africa | |
| Desmond Tutu HIV Foundation | |
| Cape Town, South Africa, 7925 | |
| Chris Hani Baragwanath Hospital | |
| Soweto, South Africa | |
| Thailand | |
| HIV-NAT Program on AIDS - Thai Red Cross | |
| Bangkok, Thailand, 10330 | |
| Principal Investigator: | Paddy Mallon | Mater Misericordiae University Hospital, Dublin |
| Principal Investigator: | Waldo Belloso | Hospital Italiano, Argentina |
| Principal Investigator: | Samuel Ferret | Hopital Saint-Louis, France |
| Principal Investigator: | Praphan Phanuphak | HIV-NAT Program on AIDS - Thai Red Cross, Bangkok |
| Principal Investigator: | Jennifer Hoy | The Alfred Hospital, Melbourne |
More Information
No publications provided
| Responsible Party: | Kirby Institute |
| ClinicalTrials.gov Identifier: | NCT01513122 History of Changes |
| Other Study ID Numbers: | 2L body comp sub-study |
| Study First Received: | January 16, 2012 |
| Last Updated: | June 10, 2013 |
| Health Authority: | Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica South Africa: Medicines Control Council India: Drugs Controller General of India |
Additional relevant MeSH terms:
|
Ritonavir Lopinavir HIV Protease Inhibitors Protease Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |
Pharmacologic Actions Anti-HIV Agents Anti-Retroviral Agents Antiviral Agents Anti-Infective Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on June 17, 2013